Showing results (81-90 of 153) with videos related to
Sort By:
Pageof 16
Bioorganic & Medicinal Chemistry Letters|April 25, 2016
Synthesis of a stable and orally bioavailable englerin analogueDavid M Fash, Cody J Peer, Zhenwu Li, et al.Journal of Thrombosis and Haemostasis : JTH|July 2, 2013
The CYP2C19*17 variant is not independently associated with clopidogrel responseJ P Lewis, S H Stephens, R B Horenstein, et al.Neuro-Oncology|February 16, 2024
Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancerVanesa L Silvestri, Andy D Tran, Monika Chung, et al.Pharmacogenetics and Genomics|February 17, 2017
Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet responseJoshua D Backman, Jeffrey R O'Connell, Keith Tanner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.ACS Medicinal Chemistry Letters|September 18, 2020
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth InhibitionZhenhua Wu, Jean-Simon Suppo, Sarka Tumova, et al.Frontiers in Pharmacology|August 31, 2016
Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in RatsCody J Peer, Jonathan D Strope, Shaunna Beedie, et al.Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.Clinical Pharmacology and Therapeutics|September 20, 2012
OATP1B1 polymorphism as a determinant of erythromycin dispositionC S Lancaster, G H Bruun, C J Peer, et al.Pageof 16